The impact of prescription drug insurance on cost related non-adherence to medications in Canada: A Heckman sample selection approach

PLoS One. 2023 Aug 9;18(8):e0289776. doi: 10.1371/journal.pone.0289776. eCollection 2023.

Abstract

Unlike some other high-income counties, Canada does not provide universal prescription drug coverage. The various extent of coverage may left some Canadians vulnerable to cost-related non-adherence (CRNA) to medications. Using data from the 2015 national cycle of the Canadian Community Health Survey, we examine the impact of having private and public drug coverage on mitigating the risk of CRNA with a logit model and a Heckman selection model. CRNA was only observed in respondents who had prescriptions to fill, and respondents did not randomly make decisions on whether to get a prescription. This results in a classic sample selection problem. We found a higher estimated probability of reporting CRNA for uninsured respondents from the Heckman selection model than from the logit model. Respondents with government coverage only had a slightly higher probability of reporting CRNA relative to respondents with private coverage. These findings suggest that, without accounting for sample selection, the risk of not having drug insurance coverage is likely to be underestimated. Moreover, despite covering a less healthy cohort of respondents, the government insurance plans reduce risk of CRNA to a comparable level with private insurance.

MeSH terms

  • Canada
  • Humans
  • Insurance Coverage
  • Insurance, Pharmaceutical Services
  • Prescription Drugs*
  • Prescriptions
  • RNA, Complementary

Substances

  • Prescription Drugs
  • RNA, Complementary

Grants and funding

The author(s) received no specific funding for this work.